Association of serum prostate-specific antigen with Complete Blood Counts in patients with prostatic cancer
Abstract
Background: Prostate cancer is the second most common cancer and one of the most leading causes of death in men worldwide. The prostate-specific antigen (PSA) as a screening method showed that there has been a slight decrease in prostate cancer mortality. Effective biomarkers in screening and diagnosis would be beneficial for avoiding unnecessary operations. The predictive and prognostic value of complete blood count (CBC) has been manifested by recent studies. We aimed to determine the association of serum PSA with Complete blood counts in patients with prostate cancer.
Method: The present study included 100 subjects, 50 patients diagnosed with new prostate cancer and 50 patients with prostate cancer. All the was undertaken in the central diagnostic laboratory at VIMS and RC. Blood samples were collected from all the subjects after taken permission from the institutional ethics committee and consent form. The haemoglobin, RBCs, MCV, MCHC, RDW will be analysed by using laboratory standard methods (Beckman coulter LH-780) and The serum PSA levels are estimated by commercially available kits based on enzyme-linked immunosorbent assay (ELISA).
Results: In the present study found significantly elevated levels of a prostate specific antigen in both groups of prostatic cancer patients. The reduced levels of hemoglobin, red blood cells, platelets, neutrophils were observed in prostatic cancer patients when compared to newly diagnosed prostate cancer patients. The PSA levels were negatively correlated with total blood counts.
Conclusion: This study suggests that the elevated levels of prostate specific antigen were useful for diagnosis and prognosis of prostatic cancers, along with the monitoring of complete blood count may be useful for the treatment of patients with prostatic cancers.
Downloads
References
Christudoss P, Selvakumar R, Fleming JJ, Gopalakrishnan G. Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma. Indian J Urol. 2011 Jan;27(1):14-8. doi: 10.4103/0970-1591.78405.
Sarwar, S., Adil, M. A. M., Nyamath, P., & Ishaq, M. Biomarkers of prostatic cancer: an attempt to categorize patients into prostatic carcinoma, benign prostatic hyperplasia, or prostatitis based on serum prostate specific antigen, prostatic acid phosphatase, calcium, and phosphorus. Prostate Cancer, 2017 (2017).
Vickers AJ. Prostate Cancer Screening: Time to Question How to Optimize the Ratio of Benefits and Harms. Ann Intern Med. 2017 Oct 3;167(7):509-510. doi: 10.7326/M17-2012.
Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 Aug 5;149(3):192-9. doi: 10.7326/0003-4819-149-3-200808050-00009.
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542-7. doi: 10.1001/jama.279.19.1542.
McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol. 1968 Mar;49(3):347-57. doi: 10.1093/ajcp/49.3.347.
Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol. 1987 Nov;138(5):1181-4. doi: 10.1016/s0022-5347(17)43543-9.
Mittal, Rama Devi, et al. "Total PSA and free PSA in patients with severe liver dysfunction." Indian Journal of Urology 19.2 (2003): 117.
Bañez LL, Loftis RM, Freedland SJ, Presti JC Jr, Aronson WJ, Amling CL, et al. The influence of hepatic function on prostate cancer outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis. 2010 Jun;13(2):173-7. doi: 10.1038/pcan.2010.3.
Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83. doi: 10.1093/jnci/djm117.
Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, Klabunde CN. National evidence on the use of shared decision making in prostate-specific antigen screening. Ann Fam Med. 2013 Jul-Aug;11(4):306-14. doi: 10.1370/afm.1539.
Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018 Sep 5;362:k3519. doi: 10.1136/bmj.k3519.
US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710.
Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018 May 8;319(18):1914-1931. doi: 10.1001/jama.2018.3712.
Sarwar S, Adil MA, Nyamath P, Ishaq M. Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus. Prostate Cancer. 2017;2017:5687212. doi: 10.1155/2017/5687212.
Vihko P, Kontturi M, Korhonen LK. Purification of human prostatic acid phosphatase by affinity chromatography and isoelectric focusing. Part I. Clin Chem. 1978 Mar;24(3):466-70.
Gunia S, Koch S, May M, Dietel M, Erbersdobler A. Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies. Virchows Arch. 2009 May;454(5):573-9. doi: 10.1007/s00428-009-0759-1.
Kirschenbaum A, Izadmehr S, Yao S, O'Connor-Chapman KL, Huang A, Gregoriades EM, Yakar S, Levine AC. Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases. Endocrinology. 2016 Dec;157(12):4526-4533. doi: 10.1210/en.2016-1606.
Larson SR, Chin J, Zhang X, Brown LG, Coleman IM, Lakely B, et al. Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clin Exp Metastasis. 2014 Feb;31(2):247-56. doi: 10.1007/s10585-013-9625-2.
Christudoss P, Selvakumar R, Fleming JJ, Gopalakrishnan G. Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma. Indian J Urol. 2011 Jan;27(1):14-8. doi: 10.4103/0970-1591.78405.
Sarwar, Shahana, Adil, M. A. M., Nyamath, P., & Ishaq, M. "Biomarkers of prostatic cancer: an attempt to categorize patients into prostatic carcinoma, benign prostatic hyperplasia, or prostatitis based on serum prostate specific antigen, prostatic acid phosphatase, calcium, and phosphorus." Prostate Cancer 2017 (2017).
Vickers AJ. Prostate Cancer Screening: Time to Question How to Optimize the Ratio of Benefits and Harms. Ann Intern Med. 2017 Oct 3;167(7):509-510. doi: 10.7326/M17-2012.
Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 Aug 5;149(3):192-9. doi: 10.7326/0003-4819-149-3-200808050-00009.
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542-7. doi: 10.1001/jama.279.19.1542.
McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol. 1968 Mar;49(3):347-57. doi: 10.1093/ajcp/49.3.347.
Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol. 1987 Nov;138(5):1181-4. doi: 10.1016/s0022-5347(17)43543-9.
Mittal, R. D., Singh, M. K., Selvaraju, C., & Choudhuri, G. Total PSA and free PSA in patients with severe liver dysfunction. Indian Journal of Urology, 19.2 (2003): 117.
Bañez LL, Loftis RM, Freedland SJ, Presti JC Jr, Aronson WJ, Amling CL, et al. The influence of hepatic function on prostate cancer outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis. 2010 Jun;13(2):173-7. doi: 10.1038/pcan.2010.3.
Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83. doi: 10.1093/jnci/djm117.
Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, et al. National evidence on the use of shared decision making in prostate-specific antigen screening. Ann Fam Med. 2013 Jul-Aug;11(4):306-14. doi: 10.1370/afm.1539.
Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018 Sep 5;362:k3519.doi: 10.1136/bmj.k3519.
US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710.
Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018 May 8;319(18):1914-1931. doi: 10.1001/jama.2018.3712.
Sarwar S, Adil MA, Nyamath P, Ishaq M. Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus. Prostate Cancer. 2017;2017:5687212.doi:10.1155/2017/5687212.
Vihko P, Kontturi M, Korhonen LK. Purification of human prostatic acid phosphatase by affinity chromatography and isoelectric focusing. Part I. Clin Chem. 1978 Mar;24(3):466-70.
Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA, Christensen IJ. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res. 2007 Jun 1;13(11):3244-9. doi: 10.1158/1078-0432.CCR-06-2616.
Schröder FH, Tombal B, Miller K, Boccon-Gibod L, Shore ND, Crawford ED, et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2010 Jul;106(2):182-7. doi: 10.1111/j.1464-410X.2009.08981.x.
Copyright (c) 2021 Author (s). Published by Siddharth Health Research and Social Welfare Society
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI - Open Archives Initiative
